Algorithm enables immunization of most individuals, with 0.7 percent developing anaphylactic reaction after one BNT162b2 dose
Guidance Updated for Assessing Allergy Risk of COVID-19 Vaccines
Janssen adenovirus type 26 vectored vaccine may be considered for individuals who self-report PEG allergy
NIH Starts Trial Looking at Rare Allergic Reactions to COVID-19 Vaccines
Research will also address biological mechanism causing the reactions and whether there is a way to predict risk
ACAAI Updates Guidance for Allergic Reactions to COVID-19 Vaccines
Guidance relates to risks for allergic reactions for mRNA (Moderna and Pfizer) and adenovirus vector (Johnson & Johnson) COVID-19 vaccines
Allergists Affirm Safety of COVID-19 Vaccines for Most
All patients should be observed for 15 minutes after vaccination; staff should be trained in anaphylaxis management
11.1 Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported
Median interval from vaccine receipt to symptom onset was 13 minutes
ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies
Pfizer COVID-19 vaccine should not be administered to individuals with a known history of severe reaction to polyethylene glycol
Alaska HCW First in U.S. to Have Allergic Reaction to COVID-19 Vaccine
Worker felt flushed within 10 minutes of receiving vaccine, followed by shortness of breath and elevated heart rate